Skip to content
Peptide.Guide
ClinicalGLP-1 & IncretinSubQWeeklyPartial data

Survodutide

BI 456906

Dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim; holds FDA Breakthrough Therapy designation for MASH with fibrosis.

Read dosing protocolJump to references

§ 01   Overview

Overview

Dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim; holds FDA Breakthrough Therapy designation for MASH with fibrosis.

Phase 2 obesity and Phase 2 MASH data published 2023–2024. SYNCHRONIZE-1 Phase 3 ongoing.

§ 02   Mechanism

Mechanism of action

Survodutide is a weekly SC peptide that co-agonizes glucagon and GLP-1 receptors. Glucagon activity is proposed to raise hepatic energy expenditure while GLP-1 suppresses appetite, with particular rationale in metabolic-associated steatohepatitis (MASH).

  • 01Weight loss comparable to tirzepatide-class in Phase 2
  • 02FDA Breakthrough Therapy designation for MASH (Sept 2024)
  • 03Hepatic fat reduction and fibrosis signal

§ 03   Dosing

Dosing protocol

Standard Protocol

Dose Range
0.6 – 6 mg weekly (trial)
Route
SubQ
Frequency
Weekly
Cycle
Phase 3 titration

§ 04   Evidence

Evidence & research

Clinical

Phase 2 obesity and Phase 2 MASH data published 2023–2024. SYNCHRONIZE-1 Phase 3 ongoing.

FDA Status

Investigational. FDA Breakthrough Therapy designation (MASH).

§ 06   News

In the news

8 articles from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

Investigational, no compounding path

Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09   Safety

Safety & side effects

Side effects

  • 01Nausea
  • 02GI effects typical of incretin class

Contraindications

None specified.

§ 10   Questions

Survodutide FAQ

What is Survodutide?
Dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim; holds FDA Breakthrough Therapy designation for MASH with fibrosis. Survodutide is a weekly SC peptide that co-agonizes glucagon and GLP-1 receptors. Glucagon activity is proposed to raise hepatic energy expenditure while GLP-1 suppresses appetite, with particular rationale in metabolic-associated steatohepatitis (MASH).
What is Survodutide used for?
Reported uses include weight loss comparable to tirzepatide-class in phase 2, fda breakthrough therapy designation for mash (sept 2024), and hepatic fat reduction and fibrosis signal. Evidence strength is rated Clinical — see the evidence section for detail.
How is Survodutide dosed?
Commonly referenced dosing is 0.6 – 6 mg weekly (trial), administered SubQ. This is educational reference only; consult a licensed clinician before use.
What are the side effects of Survodutide?
Commonly reported side effects include nausea and gi effects typical of incretin class. This list is not exhaustive.
Is Survodutide legal?
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Investigational. FDA Breakthrough Therapy designation (MASH)..

§ 11   References

Selected references

  1. 01

    Phase 2 obesity

    PMID: 37634188

  2. 02

    Phase 2 MASH

    PMID: 38856224

  3. 03

    SYNCHRONIZE-1

    NCT06066515

◆   In this categoryMore from GLP-1 & Incretin
01

Semaglutide

Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with established cardiovascular benefit.

Established
02

Tirzepatide

Dual GIP/GLP-1 receptor agonist producing greater average weight loss than semaglutide in head-to-head trials.

Established
03

Retatrutide

Investigational triple agonist (GLP-1, GIP, glucagon) producing the largest weight loss seen in Phase II trials to date.

Clinical
04

Cagrilintide

Long-acting amylin analog that slows gastric emptying and enhances satiety, typically paired with semaglutide (CagriSema).

Clinical
05

Mazdutide

Dual GLP-1 / glucagon receptor agonist showing strong weight loss and metabolic effects in late-stage trials, particularly in Asian populations.

Clinical

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.